Compare BIO-TECHNE Corp (TECH) vs Vanguard Total Stock Market Index Fund ETF (VTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Vanguard Total Stock Market Index Fund ETF — how do they compare? BIO-TECHNE Corp trades at $72.13 (market cap $11.24B), while Vanguard Total Stock Market Index Fund ETF trades at $380.49. The key difference: BIO-TECHNE Corp pays a 0.44% dividend while Vanguard Total Stock Market Index Fund ETF pays none. Which is the better fit depends on your goals.
| TECH | VTI | |
|---|---|---|
Market Cap | $11.24B | — |
Sector | Health | — |
52-Week High | $72.29 | $381.78 |
52-Week Low | $43.31 | $311.68 |
Enterprise Value | $11.32B | — |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
VTI trades at $381.78, up 0.71% with strong bullish momentum indicated by moving averages. The ETF shows institutional accumulation with multiple firms increasing positions in Q2 2026. Technical indicators show mixed signals with RSI suggesting potential overbought conditions while ADX confirms strong trend strength. Recent news highlights VTI's role as a core portfolio holding for long-term investors seeking broad market exposure.
VTI offers diversified US equity exposure with low-cost structure, though recent fee competition from competitors like BBUS presents margin pressure. The ETF's 14.53% 10-year annualized return demonstrates strong historical performance. Key risks include market concentration in large-cap tech and broader economic sensitivity. Analyst sentiment remains positive for long-term investors seeking total market diversification.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Vanguard Total Stock Market Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →
